Researchers from Philadelphia-based Temple University Health System have developed an EHR-integrated tool to detect pulmonary arterial hypertension, a form of heart failure, according to a study ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

With patient enrollment now complete, topline results are expected early next year from a Phase 3 trial testing PAH treatment ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Gradient Denervation Technologies announced today that the FDA accepted it into its Total Product Life Cycle Advisory Program ...

Gradient Denervation Technologies, a company that makes an ultrasound device for PH, will join an FDA program to speed device ...

Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions ...

A comprehensive new study from the Centers for Disease Control and Prevention’s National Center for Health Statistics shows that chronic health conditions are nearly universal among Americans age 85 ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Browns Mills, N.J.-based Deborah Heart and Lung Center named Geurys Rojas-Marte, MD, medical director of advanced heart failure and pulmonary hypertension programs, the hospital said in a June 14 ...